Cullinan Therapeutics

#TeamCullinan kicked off #NationalCancerResearchMonth at @BloodCancerUtd's #BigClimb, joining communities nationwide stepping up to support research and patients & families. Congratulations to all the climbers! #UnitedByCancerResearch #BloodCancerUnited

In autoimmune diseases, B cells mistakenly attack the body, causing ongoing symptoms. Our investigational T cell engager targeting CD19, a surface protein on B cells, aims to deplete B cells and restore balance to the immune system. Explore our fact sheet: cullinantherapeutics.com/wp-content/upl…

In partnership with @TaihoOncology and Taiho Pharmaceutical, the FDA accepted our NDA for zipalertinib for locally advanced or metastatic EGFR exon 20 insertion NSCLC following platinum‑based chemotherapy. Learn more: investors.cullinantherapeutics.com/news-releases/…

#TeamCullinan recently attended @SjogrensOrg’s National Patient Conference and @LupusOrg’s National Lupus Advocacy Summit. Thank you to the patients, caregivers, and advocates who shared their experiences and perspectives. #SjögrensDisease #LupusAdvocacy

We were honored to celebrate Nicole Barnor for being recognized as a 2026 Rising Star at @HBAnet's Global Ascension Leadership Experience event. Congratulations, Nicole! #HBAimpact #HBAWOTY26 #AscendwithHBA

For people living with Sjögren’s disease, pain and fatigue can significantly impact daily life. This #SjogrensAwarenessMonth, we’re raising awareness of these often‑invisible symptoms to advance standards of care for the community. Learn more: cullinantherapeutics.com/patients/resou…

In a new @jitcancer article, our scientists explore how targeting a unique dysregulated tumor suppressor protein with a T cell mediated therapy could offer a safe and powerful new approach for treating certain cancers. Learn more: cullinantherapeutics.com/wp-content/upl…

People living with autoimmune diseases need therapies that extend beyond symptom management. We’re exploring T cell engagers as an approach to potentially eliminate harmful B cells and modulate immune responses for durable disease control. Learn more: cullinantherapeutics.com/science/autoim…

Cancer outcomes shouldn’t depend on race or ethnicity. This #NationalMinorityCancerAwarenessMonth, we’re focused on removing barriers to access and expanding diverse participation in clinical trials. Learn more: cullinantherapeutics.com/patients/clini… #MinorityHealth

In autoimmune diseases, some B cells mistakenly attack the body, causing inflammation and ongoing symptoms. We’re investigating T cell engagers to deplete these harmful B cells, with the goal of resetting the immune system. Learn more: cullinantherapeutics.com/science/autoim…

Congratulations Nicole Barnor, Executive Director of Regulatory Affairs, for being recognized as a 2026 Rising Star by @HBAnet. Join us in celebrating Nicole! Learn more: hbagale.org/meet-honorees/… #HBAimpact #AscendWithHBA

This #WomensHistoryMonth, Amy Gubits from our Clinical Operations team shares why women’s participation in clinical trials is critical for inclusive research. Learn more: cullinantherapeutics.com/patients/clini…

This Women’s History Month, our We-GEM Community brought Team Cullinan together to build hygiene kits for women and families supported by @BHCHP in partnership with @LS_Cares.

Next week, our CMO, Jeff Jones, and VP, Translational Research, Irina Shapiro, will lead discussions on advancing clinical trials in B cell depleting and immune-resetting therapeutics. Learn more: immune-resetting-summit.com/?_bt=787528223…

We’re harnessing our team’s deep understanding of the immune system and leadership in T cell engagers to accelerate high-impact treatments for people living with autoimmune diseases and cancer. Explore how we’re moving science forward for patients in need: cullinantherapeutics.com/science/therap…

Join our partners Dr. Ricardo Grieshaber-Bouyer and @GHLForg in the lab at the University of Erlangen for an exclusive look into the promise of T cell engagers, and meet the people driving this research in autoimmune diseases. Learn more: youtube.com/watch?v=mKEdlI…

Today we shared our Q4/FY2025 financial results and corporate updates: CLN-978 initial clinical data confirmed for Q2 2026, zipalertinib 2L rolling FDA NDA submission completed & 1L study fully enrolled. investors.cullinantherapeutics.com/news-releases/…

On International Women’s Day, our Chief Scientific Officer, Jennifer Michaelson, shares how our company culture empowers women to lead, collaborate, and move meaningful science forward. Learn more: cullinantherapeutics.com/join-cullinan/… #ScienceThatMoves #IWD2026 #GivetoGain

President & CEO, Nadim Ahmed, and CMO, Jeff Jones, will participate in upcoming fireside chats at the TD Cowen 46th Annual Healthcare Conference and the Leerink Global Healthcare Conference. Learn more: investors.cullinantherapeutics.com/news-releases/… #TDCowenHealthCare

On #NationalCaregiversDay, we honor those who support people living with autoimmune diseases and cancer. Thank you to caregivers everywhere for the compassion, resilience, and hope you bring to patients. Explore our resources: cullinantherapeutics.com/patients/resou…